ERBB2 and non-small cell lung carcinoma: This comprehensive review delineates the molecular landscape and clinical phenotypes of <i>HER2</i>-altered NSCLC, synthesizes interim and mature data from ongoing clinical trials evaluating anti-<i>HER2</i> therapies, and critically examines efficacy and safety results from different classes of targeted agents.